ANN ARBOR, Mich., Sept. 22 /PRNewswire-FirstCall/ -- Esperion
Therapeutics, Inc. (Nasdaq: ESPR), a biopharmaceutical company dedicated to
the discovery, development and commercialization of therapies to improve the
treatment of cardiovascular disease, today announced that Timothy M. Mayleben,
Chief Operating Officer and Chief Financial Officer, will present at the UBS
Global Life Sciences Conference on Thursday, September 25, 2003 in New York
City. Mr. Mayleben is scheduled to speak at 11:00 a.m. (EDT).
Investors and others may access a live audio webcast of the presentation
at http://www.ibb.ubs.com by first clicking the "Conferences" box and then
clicking the webcast link for the Global Life Sciences Conference. An audio
replay of the Esperion presentation will be available until October 25, 2003.
Esperion Therapeutics
Esperion Therapeutics, Inc. discovers and develops pharmaceutical products
for the treatment of cardiovascular disease. Esperion intends to
commercialize a novel class of drugs that focuses on a new treatment approach
called "HDL Therapy," which is based on the Company's understanding of high-
density lipoprotein, or HDL, function. HDL is the primary facilitator of the
reverse lipid transport, or RLT, pathway by which excess cholesterol and other
lipids are removed from artery walls and other tissues and are transported to
the liver for elimination from the body. Esperion's goal is to develop drugs
that exploit the beneficial functions of HDL within the RLT pathway. Esperion
currently has four product candidates in clinical development. Esperion is
listed on the Nasdaq National Market under the symbol "ESPR."
Company Amy Cannon
Contact: Manager, Corporate Communications
Esperion Therapeutics, Inc.
(734) 222-1801
acannon@esperion.com
SOURCE Esperion Therapeutics, Inc.
 back to top
Related links:
http://www.esperion.com
http://www.ibb.ubs.com
CONTACT:
Amy Cannon, Manager, Corporate Communications
of Esperion Therapeutics, Inc., +1-734-222-1801,
acannon@esperion.com
|
